Document 0214
 DOCN  M9650214
 TI    Treatment with an anti-CD4 monoclonal antibody strongly ameliorates
       established rat adjuvant arthritis.
 DT    9605
 AU    Pelegri C; Morante MP; Castellote C; Franch A; Castell M; Unit of
       Physiology, Faculty of Pharmacy, University of Barcelona,; Spain.
 SO    Clin Exp Immunol. 1996 Feb;103(2):273-8. Unique Identifier : AIDSLINE
       MED/96152676
 AB    Some experimental arthritic diseases can be prevented by treatment with
       anti-CD4 MoAbs. Trials with ongoing disease have not been successful so
       far. The aim of this study was to ascertain whether W3/25 could reverse
       adjuvant arthritis (AA), when beginning treatment on day 14, i.e. when
       the disease was established. Moreover, one group of animals treated with
       the anti-CD4 MoAb received OX8 MoAb at the same time, thus depleting
       CD8+ cells from circulation. During treatment with W3/25, a strong
       amelioration of inflammatory signals were observed, as assessed by means
       of paw volume increase and arthritic score. However, when treatment
       stopped, a rebound to arthritis signals occurred. The parallel depletion
       of CD8+ cells did not modify these effects, thus the combined treatment
       W3/25 + OX8 gave the same amelioration as treatment with W3/25 alone.
       These findings indicate that CD4+ cells play an important role in
       perpetuating rat AA. Moreover, CD8+ cells do not seem to have a
       regulatory role int he CD4+ cells responsible for the inflammatory
       response.
 DE    Animal  Antibodies, Monoclonal/*THERAPEUTIC USE  Antigens,
       CD4/*IMMUNOLOGY  Antigens, CD8/IMMUNOLOGY  Arthritis,
       Adjuvant/*IMMUNOLOGY/THERAPY  CD4-Positive T-Lymphocytes/IMMUNOLOGY
       CD8-Positive T-Lymphocytes/IMMUNOLOGY  Female  Rats  Rats, Wistar
       Support, Non-U.S. Gov't  Time Factors  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).